EKSO BIONICS HOLDINGS INC (EKSO) Fundamental Analysis & Valuation

NASDAQ:EKSO • US2826444000

Current stock price

9.02 USD
+1 (+12.47%)
At close:
8.9899 USD
-0.03 (-0.33%)
After Hours:

This EKSO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EKSO Profitability Analysis

1.1 Basic Checks

  • In the past year EKSO has reported negative net income.
  • EKSO had a negative operating cash flow in the past year.
  • In the past 5 years EKSO always reported negative net income.
  • EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • EKSO's Return On Assets of -59.28% is on the low side compared to the rest of the industry. EKSO is outperformed by 72.34% of its industry peers.
  • EKSO has a Return On Equity of -132.06%. This is in the lower half of the industry: EKSO underperforms 70.74% of its industry peers.
Industry RankSector Rank
ROA -59.28%
ROE -132.06%
ROIC N/A
ROA(3y)-51.45%
ROA(5y)-42.63%
ROE(3y)-113.93%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

1.3 Margins

  • EKSO has a Gross Margin (53.48%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of EKSO has remained more or less at the same level.
  • EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.6%
GM growth 5Y-1.3%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. EKSO Health Analysis

2.1 Basic Checks

  • EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EKSO has more shares outstanding
  • The number of shares outstanding for EKSO has been increased compared to 5 years ago.
  • Compared to 1 year ago, EKSO has a worse debt to assets ratio.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • EKSO has an Altman-Z score of -17.73. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of EKSO (-17.73) is worse than 87.23% of its industry peers.
  • EKSO has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.31, EKSO perfoms like the industry average, outperforming 48.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -17.73
ROIC/WACCN/A
WACC8.09%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.63 indicates that EKSO should not have too much problems paying its short term obligations.
  • The Current ratio of EKSO (1.63) is worse than 73.40% of its industry peers.
  • A Quick Ratio of 1.07 indicates that EKSO should not have too much problems paying its short term obligations.
  • EKSO's Quick ratio of 1.07 is on the low side compared to the rest of the industry. EKSO is outperformed by 79.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.07
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. EKSO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.57% over the past year.
  • The Revenue for EKSO has decreased by -28.60% in the past year. This is quite bad
  • Measured over the past years, EKSO shows a small growth in Revenue. The Revenue has been growing by 7.59% on average per year.
EPS 1Y (TTM)42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
Revenue 1Y (TTM)-28.6%
Revenue growth 3Y-0.29%
Revenue growth 5Y7.59%
Sales Q2Q%-38.31%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.46% on average over the next years. This is a very strong growth
  • EKSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.67% yearly.
EPS Next Y91.48%
EPS Next 2Y40.98%
EPS Next 3Y26.12%
EPS Next 5Y22.46%
Revenue Next Year54.65%
Revenue Next 2Y28.81%
Revenue Next 3Y27.67%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

1

4. EKSO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EKSO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EKSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • EKSO's earnings are expected to grow with 26.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.98%
EPS Next 3Y26.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EKSO Dividend Analysis

5.1 Amount

  • EKSO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EKSO Fundamentals: All Metrics, Ratios and Statistics

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (4/10/2026, 8:19:05 PM)

After market: 8.9899 -0.03 (-0.33%)

9.02

+1 (+12.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-23
Earnings (Next)05-04
Inst Owners23.97%
Inst Owner Change37.1%
Ins Owners25.25%
Ins Owner Change0.42%
Market Cap32.11M
Revenue(TTM)12.80M
Net Income(TTM)-11.92M
Analysts80
Price Target9.69 (7.43%)
Short Float %10.07%
Short Ratio1.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-151.88%
Min EPS beat(2)-357.52%
Max EPS beat(2)53.76%
EPS beat(4)2
Avg EPS beat(4)-75.19%
Min EPS beat(4)-357.52%
Max EPS beat(4)53.76%
EPS beat(8)4
Avg EPS beat(8)-48.29%
EPS beat(12)5
Avg EPS beat(12)-39.26%
EPS beat(16)7
Avg EPS beat(16)-30.81%
Revenue beat(2)0
Avg Revenue beat(2)-21.7%
Min Revenue beat(2)-38.74%
Max Revenue beat(2)-4.65%
Revenue beat(4)0
Avg Revenue beat(4)-31.27%
Min Revenue beat(4)-53.24%
Max Revenue beat(4)-4.65%
Revenue beat(8)0
Avg Revenue beat(8)-23.22%
Revenue beat(12)3
Avg Revenue beat(12)-11.29%
Revenue beat(16)3
Avg Revenue beat(16)-11.24%
PT rev (1m)0%
PT rev (3m)22.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.51%
EPS NY rev (1m)0%
EPS NY rev (3m)43.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.51
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB 6.3
EV/EBITDA N/A
EPS(TTM)-4.91
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-3.37
FCFYN/A
OCF(TTM)-3.31
OCFYN/A
SpS3.6
BVpS2.54
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.28%
ROE -132.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.48%
FCFM N/A
ROA(3y)-51.45%
ROA(5y)-42.63%
ROE(3y)-113.93%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.6%
GM growth 5Y-1.3%
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.95%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.07
Altman-Z -17.73
F-Score3
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)7.83%
Cap/Depr(5y)11.11%
Cap/Sales(3y)0.84%
Cap/Sales(5y)0.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
EPS Next Y91.48%
EPS Next 2Y40.98%
EPS Next 3Y26.12%
EPS Next 5Y22.46%
Revenue 1Y (TTM)-28.6%
Revenue growth 3Y-0.29%
Revenue growth 5Y7.59%
Sales Q2Q%-38.31%
Revenue Next Year54.65%
Revenue Next 2Y28.81%
Revenue Next 3Y27.67%
Revenue Next 5YN/A
EBIT growth 1Y-25.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.86%
OCF growth 3YN/A
OCF growth 5YN/A

EKSO BIONICS HOLDINGS INC / EKSO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EKSO BIONICS HOLDINGS INC?

ChartMill assigns a fundamental rating of 2 / 10 to EKSO.


What is the valuation status for EKSO stock?

ChartMill assigns a valuation rating of 1 / 10 to EKSO BIONICS HOLDINGS INC (EKSO). This can be considered as Overvalued.


How profitable is EKSO BIONICS HOLDINGS INC (EKSO) stock?

EKSO BIONICS HOLDINGS INC (EKSO) has a profitability rating of 1 / 10.